Claims for Patent: 5,008,283

Summary for Patent: 5,008,283

Title:	Use of tenidap to inhibit activation of collagenase and to inhibit the activity of myeloperoxidase
Abstract:	This invention relates to the use of tenidap, 5-chloro-2,3-dihydro-2-oxo-3-(2-thienylcarbonyl)-indole-1-carboxamide, and the pharmaceutically-acceptable base salts thereof to inhibit activation of collagenase in a mammal and to inhibit the activity of myeloperoxidase in a mammal. This invention also relates to the use of tenidap and its salts for treating collagenase mediated disorders and diseases such as bone resorption disorders, corneal ulceration, periodontal disease, inflammatory disease and wounds of the skin and burns in mammals. The methods of this invention comprise administering an effective amount of tenidap or salts thereof to a mammal.
Inventor(s):	Blackburn, Jr.; Warren D. (Groton, CT), Loose; Leland D. (Groton, CT)
Assignee:	Pfizer Inc. (New York, NY)
Application Number:	07/495,868
Patent Claims:	1. A method of inhibiting activation of collagenase in a mammal in need thereof which comprises administering to said mammal a collagenase activation inhibiting amount of tenidap or a pharmaceutically-acceptable base salt thereof. 2. The method according to claim 1 wherein tenidap or a pharmaceutically-acceptable base salt thereof is administered orally. 3. The method according to claim 1 wherein tenidap or a pharmaceutically-acceptable base salt thereof is administered parenterally. 4. A method of treating a collagenase-mediated disorder or disease in a mammal which comprises administering to said mammal a collagenase-mediated disorder or disease treating amount of tenidap or a pharmaceutically-acceptable base salt thereof. 5. The method according to claim 4 wherein tenidap or a pharmaceutically-acceptable base salt thereof is administered orally. 6. The method according to claim 4 wherein tenidap or a pharmaceutically-acceptable base salt thereof is administered parenterally. 7. The method according to claim 4 wherein the collagenase-mediated disorder is bone resorption disorder. 8. The method according to claim 7 wherein the bone resorption disorder is osteoporosis or metastatic bone cancer. 9. The method according to claim 4 wherein the collagenase-mediated disorder or disease is corneal ulceration. 10. The method according to claim 9 wherein tenidap or a pharmaceutically-acceptable base salt thereof is administered topically. 11. The method according to claim 4 wherein the collagenase-mediated disorder or disease is periodontal disease. 12. The method according to claim 10 wherein tenidap or a pharmaceutically-acceptable base salt thereof is administered topically. 13. The method according to claim 4 wherein the collagenase-mediated disorder or disease is an inflammatory disease or wound of the skin in a mammal. 14. The method according to claim 11 wherein tenidap or a pharmaceutically-acceptable base salt thereof is administered topically. 15. A method of treating burns of the skin of a mammal which comprises administering to said mammal a burn treating amount of tenidap or a pharmaceutically-acceptable base salt thereof. 16. The method according to claim 15 wherein tenidap or a pharmaceutically-acceptable base salt thereof is administered orally. 17. The method according to claim 15 wherein tenidap or a pharmaceutically-acceptable base salt thereof is administered parenterally. 18. The method according to claim 17 wherein said parenteral administration comprises administering tenidap or a pharmaceutically-acceptable base salt thereof topically. 19. A method of inhibiting the activity of myeloperoxidase in a mammal in need thereof which comprises administering to said mammal a myeloperoxidase inhibiting amount of tenidap or a pharmaceutically-acceptable base salt thereof. 20. The method according to claim 19 wherein tenidap or a pharmaceutically-acceptable base salt thereof is administered orally. 21. The method according to claim 19 wherein tenidap or a pharmaceutically-acceptable base salt thereof is administered parenterally.

Details for Patent 5,008,283

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2039-02-26